Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 2, 2007, Pages 130-135

  Hahn, S ^a   Tan, S ^a   Sack, S ^a   Kimmig, R ^a   Quadbeck, B ^a   Mann, K ^a   Janssen, O E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Hyperandrogenism; Metabolic syndrome; Obesity; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANAMNESIS; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHTS AND MEASURES; COHORT STUDIES; COMORBIDITY; FEMALE; GERMANY; HUMANS; LIPIDS; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PREVALENCE;

EID: 33947119276     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-967093     Document Type: Article

References (43)

1. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749
3. Berlin JA, Colditz GA: A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-628
4. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-2165
5. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA: Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006; 154: 141-145
6. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA: Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2562-2568
7. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71: 599-604
8. Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I, Turpin G: Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 2001; 54: 455-462
9. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH: Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106: 131-137
10. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
11. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146
12. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN: Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005a; 90: 66-71
13. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2005b; Epub Oct 25. 2006; 91: 48-53
14. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J: Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001; 16: 556-560
15. ESHRE/ASRM Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
16. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-915
17. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG: Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 2003; 52: 713-719
18. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H: Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996; 11: 23-28
19. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
20. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455
21. Kim MH, Kim MK, Choi BY, Shin YJ: Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea. J Korean Med Sci 2004; 19: 195-201
22. Lee WY, Jung CH, Park JS, Rhee EJ, Kim SW: Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III. Diabetes Res Clin Pract 2005; 67: 70-77
23. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312
24. Legro RS, Kunselman AR, Dunaif A: Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613
25. Masuo K, Mikami H, Ogihara T, Tuck ML: Familial obesity, sympathetic activation and blood pressure level. Blood Press 2001; 10: 199-204
26. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
27. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW: Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464
28. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS: Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000; 15: 1266-1274
29. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel). JAMA 2001; 285: 2486-2497
30. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89
31. Ohrvall M, Berglund L, Vessby B: Sagittal abdominal diameter compared with other anthropometric measurements in relation to cardiovascular risk. Int J Obes Relat Metab Disord 2000; 24: 497-501
32. Peiris AN, Sothmann MS, Aiman EJ, Kissebah AH: The relationship of insulin to sex hormone-binding globulin: role of adiposity. Fertil Steril 1989; 52: 69-72
33. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S: Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996; 44: 277-284
34. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA: Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51: 415-422
35. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998; 148: 958-966
36. Turcato E, Bosello O, Di Francesco V, Harris TB, Zoico E, Bissoli L, Fracassi E, Zamboni M: Waist circumference and abdominal sagittal diameter as surrogates of body fat distribution in the elderly: their relation with cardiovascular risk factors. Int J Obes Relat Metab Disord 2000; 24: 1005-1010
37. Vrbikova J, Cifkova R, Jirkovska A, Lanska V, Platilova H, Zamrazil V, Starka L: Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003; 18: 980-984
38. Vrbikova J, Vondra K, Cibula D, Dvorakova K, Stanicka S, Sramkova D, Sindelka G, Hill M, Bendlova B, Skrha J: Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005; 20: 3328-3332
39. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE: Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002; 57: 343-350
40. Wild RA: Long-term health consequences of PCOS. Hum Reprod Update 2002; 8: 231-241
41. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951
42. Wild S, Pierpoint T, McKeigue P, Jacobs H: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600
43. Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM: Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 1995; 80: 3227-3232